



Accreditation Statement



In support of improving patient care, American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Target Audience Statement

The field of Addiction changes frequently as new information becomes available. This course presents a broad-based overview of addictions and up-to-date information in the field of addiction. It is recommended for physicians, PA-Cs, nurse practitioners, and other professionals who wish to stay updated on the most recent trends in the addiction field. It is equally relevant to junior faculty and clinicians as well as experienced practitioners and is intended to help psychiatrists prepare for ABPN certification and recertification examinations in Addiction Psychiatry.

The activity was designated for learners in the following ways:

Physician Designation Statement

American Academy of Addiction Psychiatry designates this enduring material for a maximum of 28.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABPN Diplomates

The American Board of Psychiatry and Neurology has reviewed AAAP's 2025 Addictions and Their Treatment and has approved this program as part of a comprehensive self-assessment program, which is mandated by the ABMS as a necessary component of maintenance of certification. This activity awards 2.5 Self-Assessment Category 1 CME Credits. The approval period is through September 12, 2028.

AAPA Designation Statement

PAs may claim a maximum of 28.25 Category 1 credits for completing this activity. NCCPA accepts *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioners and Registered Nurses

For the purpose of recertification, the American Nurses Credentialing Center accepts *AMA PRA Category 1 Credit™* issued by organizations accredited by the ACCME.

Health Professionals Designation Statement

Participants will receive a Certificate of Attendance stating this program is designated for 28.25 *AMA PRA Category 1 Credits™*. This credit is accepted by the AANP.

Educational Objectives:

After participating in this course, learners should be able to:

1. Describe new advances in pharmacotherapy and psychotherapy of substance use disorders.
2. Discuss the epidemiology of substance use disorders and their co-occurrence with other psychiatric conditions and review current recommended approaches for concurrent treatment of substance use disorders and other conditions.
3. Describe the role of genetics in the risk for developing substance use disorders.
4. Identify the major neurobiological pathways involved in substance use disorders.
5. Identify the molecular mechanisms that are altered following substance use disorder.
6. Review strategies for screening, brief intervention, and referral to treatment in the context of motivational interviewing.
7. Review current treatment guidelines and how to utilize them in clinical practice.
8. Describe special considerations for substance use disorder diagnosis and treatment for women, underrepresented racial and ethnic minorities, youth, older adults, hospitalized patients, and patients with comorbid health conditions.

Topic	Faculty
Behavioral Addictions	Timothy W. Fong, MD
Co-Morbidity of Substance and other Psychiatric Disorders	Edward V. Nunes, MD
Party Drugs	Petros Levounis, MD, MA
Access in Addiction Treatment for Special Populations	Adina Bowe, MD
Pain and Addiction	Roger Chou, MD
Pregnancy and Substance Use Disorders	Michelle Lofwall, MD
Substance Use Disorders in the Older Population	Louis Trevisan, MD
Youth and Substance Use Disorders and Attention Deficit Hyperactivity Disorder	Amy M. Yule, MD
Sex and Gender Differences in Substance Use Disorder	Kathleen T. Brady, MD, PhD
Suicide and Substance Use Disorders	Richard Ries, MD
Integrative Care	Sanchi Maruti, MD
Hot Topics	Joshua Lee, MD
Alcohol	David Marcovitz, MD
Cannabis	Petros Levounis, MD, MA
Benzodiazepines: The Hidden Epidemic	Richard K. Ries, MD
Forensic Issues in Addiction	Laurence M. Westreich, MD
General Concepts and Epidemiology	Kevin A. Sevarino, MD, PhD
Medical Comorbidities in Patients with Substance Use Disorders	Steven L. Batki, MD
Motivational Interviewing	Carla Marienfeld, MD
Naloxone Overdose Training	Michelle Lofwall, MD
Neurobiology and Genetics	Kevin A. Sevarino, MD, PhD
Psychosocial Treatments of the Addictions	Edward V. Nunes, MD
Review of Opioids and Treatment of Opioid Use Disorders	John A. Renner, Jr., MD
Stimulant-Related Disorders	Steven L. Batki, MD

Topic	Faculty
Substance Use Disorder in Hospital Settings	Sanchi Maruti, MD
Tobacco and Nicotine	Jill Williams, MD
Urine Drug Testing	Kevin A. Sevarino, MD, PhD

Disclosure to Learners:

In accordance with the disclosure policy of the American Academy of Addiction Psychiatry, as well as standards set forth by JAC policies and guidelines and the ACCME, the JAC expects accredited providers to present learners with unbiased, independent, and objective information in all activities. Accredited providers must be in compliance with the Standards for Integrity and Independence in Accredited Continuing Education. Therefore, Presenter(s), Planner(s), Reviewer(s), and all others involved in the planning or content development of this activity were required to disclose all financial relationships within the past 24 months.

For this activity, the following relevant financial relationships were disclosed:

Michelle Lofwall, MD	Braeburn Pharmaceuticals	Scientific Advisor
	Berkshire Biomedical	Scientific Advisor
	Camurus	Honoraria
Edward V. Nunes, MD	Alkermes	Investigator/In-kind donation
	Braeburn Pharmaceuticals	Investigator/In-kind donation
	Camurus	Investigator/In-kind donation
	CHESS Health	Investigator/In-kind donation
	Pear Therapeutics	Investigator/In-kind donation

All disclosures have been reviewed and all relevant financial relationships have been mitigated.

All other individuals involved in the planning and presentation of this activity have no relevant financial relationships with ineligible companies to disclose.

All speakers have been advised that any recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in the presentation must conform to the generally accepted standards of experimental design, data collection, and analysis. Faculty have also been advised that they must not actively promote or sell products or services that serve their professional or financial interests during accredited education.

Breakdown of Credit:

On-Demand Recorded Lectures		CME Credits
Reused from 2023: 2023 On Demand Presentations and Live Q&A		
1 Hour 15 Minutes	Forensic Issues in Addiction Presentation Forensic Issues in Addiction Q&A	1.25
1 Hour 2 minutes 18 Minutes	Medical Comorbidities in Patients with Substance Use Disorders Presentation Medical Comorbidities in Patients with Substance Use Disorders Live Q&A	0.0
44 Minutes 19 Minutes	Motivational Interviewing Presentation Motivational Interviewing Live Q&A	1.0
23 Minutes 16 Minutes	Naloxone Overdose Training Presentation Naloxone Overdose Training Live Q&A	.75
1 Hour 2 minutes 16 Minutes	Substance Use Disorders in Hospital Settings Presentation Substance Use Disorders in Hospital Settings Live Q&A	1.25
		4.25
Reused from 2024: Recorded 2024 Live Lectures & Q&As		
1 Hour 1 Minute	Alcohol Presentation & Q&A	1.0
53 Minutes	Cannabis Presentation & Q&A	1.0
59 Minutes	Benzodiazepines: The Hidden Epidemic Presentation & Q&A	1.0
1 Hour 3 Minutes	General Concepts and Epidemiology Presentation & Q&A	1.0
54 Minutes	Neurobiology and Genetics Presentation & Q&A	1.0
1 Hour 4 Minutes	Psychosocial Treatments of the Addictions Presentation & Q&A	1.0
1 Hour 15 Minutes	Review of Opioids and Treatment of Opioid Use Disorders Presentation & Q&A	1.25
1 Hour 1 Minute	Stimulant-Related Disorders Presentation & Q&A	1.0
1 Hour	Tobacco and Nicotine Presentation & Q&A	1.0
45 Minutes	Urine Drug Testing Presentation & Q&A	.75
		10.0
Recorded 2025 Live Lectures & Q&As		
54 Minutes	Suicide and Substance Use Disorders Presentation & Q&A	1.0
56 Minutes	Behavioral Addictions Presentation & Q&A	1.0
58 Minutes	Co-Morbidity of Substance and other Psychiatric Disorders Presentation & Q&A	1.0
50 Minutes	Integrative Care Presentation & Q&A	.75
50 Minutes	Party Drugs Presentation & Q&A	.75
57 Minutes	Hot Topics Presentation & Q&A	1.0
62 Minutes	Pregnancy and Substance Use Disorders Presentation & Q&A	1.0
55 Minutes	Substance Uder Disorders in the Older Population Presentation & Q&A	1.0
58 Minutes	Youth with Substance Use Disorders and Attention Deficit Hyperactivity Disorder Presentation & Q&A	1.0
54 Minutes	Sex and Drugs Gender Differences in Substance Use Disorder Presentation & Q&A	1.0
60 Minutes	Pain and Addiction Presentation & Q&A	1.0
53 Minutes	Access in Addiction Treatment for Special Populations Presentation & Q&A	1.0
		11.5

Maximum Credit	CME Credits	SA Credits
2023 On Demand Presentations and Live Q&A	4.25	0
Recorded 2024 Live Lectures & Q&As	10.0	0
Recorded 2025 Live Lectures & Q&As	11.5	0
Self-Assessment Exam	2.5	2.5
Grand total 28.25 <i>AMA PRA Category 1 Credits™</i>		2.5 SA CME